TAK-147 (Takeda).
TAK-147 is a CNS-specific acetylcholinesterase inhibitor under development by Takeda as a potential treatment for Alzheimer's disease. By November 1999, it had entered phase III trials in Japan [348496]. In August 1999, Lehman Brothers predicted product launch in 2002, with potential peak sales of $250 million in 2012 [349228].